Diagnosis and management of antibody-mediated rejection: Current status and novel approaches

American Journal of Transplantation

Volumn 14, Issue 2, 2014, Pages 255-271

  Djamali, A ^a   Kaufman, D B ^a   Ellis, T M ^a   Zhong, W ^a,b   Matas, A ^c   Samaniego, M ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antibody mediated rejection; complement C4d; donor specific antibodies; phenotype

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; BIOLOGICAL MARKER; BORTEZOMIB; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CYCLOSPORIN; ECULIZUMAB; EVEROLIMUS; HLA ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ALLOANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; B LYMPHOCYTE; CHRONIC GRAFT REJECTION; DESENSITIZATION; DIAGNOSTIC APPROACH ROUTE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOADSORPTION; IMMUNOBIOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; BLOOD; GRAFT REJECTION; IMMUNOLOGY; ORGAN TRANSPLANTATION;

GRAFT REJECTION; HUMANS; ISOANTIBODIES; ORGAN TRANSPLANTATION;

EID: 84895061441     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12589     Document Type: Review

References (149)

1. Coll E, Crespo M, Solé M, et al. Lessons from cyclosporine monotherapy in renal transplantation: The impact of acute rejection on long-term allograft outcome. Transplant Proc 2004; 36 (Suppl): S114-S116.
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D., Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
3. Meier-Kriesche HJ, Schold JD, Srinivas TR, Kaplan B., Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.
4. Meier-Kriesche HU, Schold JD, Kaplan B., Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies ? Am J Transplant 2004; 4: 1289-1295.
5. Lamb KE, Lodhi S, Meier-Kriesche HU., Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011; 11: 450-462.
6. Organ Procurement and Transplant Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR). 2011 Annual Report. Available at: http://www.srtr.org/annual-reports/. Accessed June 3, 2013.
7. Djamali A, Samaniego M, Muth B, et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol 2006; 1: 623-640.
8. Halloran PF., Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
9. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD., A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6 (5 Pt 1): 876-883.
10. Jordan SC, Pescovitz MD., Presensitization: The problem and its management. Clin J Am Soc Nephrol 2006; 1: 421-432.
11. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S., A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351.
12. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
13. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
14. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
15. Farkash EA, Colvin RB., Diagnostic challenges in chronic antibody-mediated rejection. Nat Rev Nephrol 2012; 8: 255-257.
16. Sis B, Halloran PF., Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010; 15: 42-48.
17. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10: 1812-1822.
18. Drachenberg CB, Papadimitriou JC., Endothelial injury in renal antibody-mediated allograft rejection: A schematic view based on pathogenesis. Transplantation 2013; 95: 1073-1083.
19. Lynch RJ, Silva IA, Chen BJ, Punch JD, Cascalho M, Platt JL., Cryptic B cell response to renal transplantation. Am J Transplant 2013; 13: 1713-1723.
20. Cascalho MI, Chen BJ, Kain M, Platt JL., The paradoxical functions of B cells and antibodies in transplantation. J Immunol 2013; 190: 875-879.
21. Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
22. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS., The significance of the anti-class I antibody response: I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990; 49: 85-91.
23. Halloran PF, Schlaut J, Solez K, Srinivasa NS., The significance of the anti-class I response: II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550-555.
24. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338.
25. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214.
26. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582.
27. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380.
28. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
29. Racusen LC, Halloran PF, Solez K., Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant 2004; 4: 1562-1566.
30. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
31. Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int 2012; 81: 628-639.
32. Haas M., C4d-negative antibody-mediated rejection in renal allografts: Evidence for its existence and effect on graft survival. Clin Nephrol 2011; 75: 271-278.
33. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56-65.
34. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF., Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
35. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
36. Sellarés J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971-983.
37. Opelz G, Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570-1576.
38. Benichou G, Yamada Y, Aoyama A, Madsen JC., Natural killer cells in rejection and tolerance of solid organ allografts. Curr Opin Organ Transplant 2011; 16: 47-53.
39. Morris PJ, Williams GM, Hume DM, Mickey MR, Terasaki PI., Serotyping for homotransplantation: XII. Occurrence of cytotoxic antibodies following kidney transplantation in man. Transplantation 1968; 6: 392-399.
40. McKenna RM, Takemoto SK, Terasaki PI., Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319-326.
41. Zou Y, Stastny P, Süsal C, Döhler B, Opelz G., Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293-1300.
42. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132-2143.
43. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
44. Lefaucheur C, Antoine C, Suberbielle C, Glotz D., Mastering the risk of HLA antibodies in kidney transplantation: An algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant 2011; 11: 1592-1598.
45. Loupy A, Lefaucheur C, Vernerey D, et al. Outcome and therapeutic approaches in acute rejection with vascular lesions and DSAs. Am J Transplant 2011; 11 (Suppl 2, Abstract #546): 193.
46. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23: 2061-2071.
47. Niederhaus SV, Muth B, Lorentzen DF, et al. Luminex-based desensitization protocols: The University of Wisconsin initial experience. Transplantation 2011; 92: 12-17.
48. Djamali A, Muth B, Ellis TM, et al. Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients. Kidney Int 2013; 83: 1185-1192.
49. Singh N, Djamali A, Lorentzen D, et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010; 90: 1079-1084.
50. Campos EF, Tedesco-Silva H, Machado PG, Franco M, Medina-Pestana JO, Gerbase-DeLima M., Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316-2320.
51. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76-85.
52. Zhang X, Reed EF., Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459-2465.
53. Valenzuela NM, Hong L, Shen XD, et al. Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant 2013; 13: 299-311.
54. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896-906.
55. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
56. Tyan DB., New approaches for detecting complement-fixing antibodies. Curr Opin Organ Transplant 2012; 17: 409-415.
57. Gebel HM, Bray RA., The evolution and clinical impact of human leukocyte antigen technology. Curr Opin Nephrol Hypertens 2010; 19: 598-602.
58. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
59. Halloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223-2230.
60. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
61. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063-1071.
62. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE., Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59: 334-341.
63. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
64. Poduval RD, Kadambi PV, Josephson MA, et al. Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection. Transplantation 2005; 79: 228-235.
65. Kedainis RL, Koch MJ, Brennan DC, Liapis H., Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant 2009; 9: 812-819.
66. Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569.
67. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G., Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003; 76: 395-400.
68. Vidard L, Kovacsovics-Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL., Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol 1996; 156: 2809-2818.
69. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
70. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576-585.
71. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124-2132.
72. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-1179.
73. Ben-Dov IZ, Muthukumar T, Morozov P, Mueller FB, Tuschl T, Suthanthiran M., MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation 2012; 94: 1086-1094.
74. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013; 95: 1113-1119.
75. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB., Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12-17.
76. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB., C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342-347.
77. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD., Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2007; 7: 2809-2815.
78. Smith JD, Hamour IM, Banner NR, Rose ML., C4d fixing, luminex binding antibodies-A new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809-2815.
79. Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 22: 982-989.
80. Blume OR, Yost SE, Kaplan B., Antibody-mediated rejection: Pathogenesis, prevention, treatment, and outcomes. J Transplant 2012; 2012: 201754.
81. Amico P, Hönger G, Steiger J, Schaub S., Utility of the virtual crossmatch in solid organ transplantation. Curr Opin Organ Transplant 2009; 14: 656-661.
82. Bingaman AW, Murphey CL, Palma-Vargas J, Wright F., A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86: 1864-1868.
83. Morath C, Opelz G, Zeier M, Süsal C., Prevention of antibody-mediated kidney transplant rejection. Transpl Int 2012; 25: 633-645.
84. Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II., The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. Transplantation 2004; 78: 190-193.
85. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH-IG02 trial. J Am Soc Nephrol 2004; 15: 3256-3262.
86. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251.
87. Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012; 94: 165-171.
88. Kozlowski T, Andreoni K., Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time ? Ann Transplant 2011; 16: 19-25.
89. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 2012; 94: 345-351.
90. Noel C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20: 1385-1392.
91. Thibaudin D, Alamartine E, de Filippis JP, Diab N, Laurent B, Berthoux F., Advantage of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998; 13: 711-715.
92. Mako M, Hager D, Muth B, Kaufman D, Ellis T, Djamali A., Thymoglobulin is associated with a significant reduction in de novo donor-specific antibodies and antibody mediated rejection in moderately sensitized renal transplant recipients. Am J Transplant 2013; 13 (Suppl 5, Abstract #265): 113.
93. Chandraker A, Guleria I, Ikle D, et al. Development of de novo anti-HLA abs in kidney transplant recipients: Final analysis of the NIH CTOT02 study. Am J Transplant 2013; 13 (Suppl 5, Abstract #268): 113.
94. Harmon W, Guleria I, Ikle D, et al. Children develop de novo anti-HLA antibodies (Abs) following kidney transplantation at a higher incidence than adults: An analysis of the NIH CTOT/CCTPT-02 study. Am J Transplant 2013; 13 (Suppl 5, Abstract #21): 36-337.
95. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
96. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: Longer-term outcomes. Am J Transplant 2009; 9: 536-542.
97. Morgan RD, O'Callaghan JM, Knight SR, Morris PJ., Alemtuzumab induction therapy in kidney transplantation: A systematic review and meta-analysis. Transplantation 2012; 93: 1179-1188.
98. Lü TM, Yang SL, Wu WZ, Tan JM., Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Chin Med J (Engl) 2011; 124: 664-668.
99. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909-1919.
100. Knechtle SJ, Pirsch JD, H Fechner J, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722-730.
101. Bloom D, Chang Z, Pauly K, et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009; 9: 1835-1845.
102. Todeschini M, Cortinovis M, Perico N, et al. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. J Immunol 2013; 191: 2818-2828.
103. Barnett AN, Hadjianastassiou VG, Mamode N., Rituximab in renal transplantation. Transpl Int 2013; 26: 563-575.
104. van den Hoogen M, Steenbergen E, Hoitsma A, Hilbrands L., Rituximab to prevent renal allograft rejection; a randomized, double-blind, placebo-controlled trial. Am J Transplant 2013; 13 (Suppl 5, Abstract #266.1): 112.
105. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K., Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469-476.
106. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
107. Everly MJ, Everly JJ, Terasaki PI., Role of proteasome inhibition in sensitized transplant candidates. Chin Med J (Engl) 2011; 124: 771-774.
108. Everly MJ, Terasaki PI, Trivedi HL., Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation 2012; 93: 572-577.
109. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
110. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: http://www.clinicaltrials.gov/. Accessed June 3, 2013.
111. Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 2013; 95: 852-858.
112. Melcher ML, Leeser DB, Gritsch HA, et al. Chain transplantation: Initial experience of a large multicenter program. Am J Transplant 2012; 12: 2429-2436.
113. Roodnat JI, Kal-van Gestel JA, Zuidema W, et al. Successful expansion of the living donor pool by alternative living donation programs. Am J Transplant 2009; 9: 2150-2156.
114. Segev DL, Gentry SE, Warren DS, Reeb B, Montgomery RA., JAMA 2005; 293: 1883-1890.
115. Almeshari K, Pall A, Chaballout A, et al. Targeted monitoring of donor-specific HLA antibodies following renal transplantation. Clin Transplant 2011; 395-400.
116. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192-1198.
117. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: A randomized phase II study. Clin J Am Soc Nephrol 2011; 6: 430-439.
118. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630-639.
119. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210-217.
120. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453.
121. Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK., Antibody-mediated rejection in kidney transplantation: An update. Expert Opin Pharmacother 2011; 12: 579-592.
122. Roberts DM, Jiang SH, Chadban SJ., The treatment of acute antibody-mediated rejection in kidney transplant recipients: A systematic review. Transplantation 2012; 94: 775-783.
123. Böhmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: A randomized controlled trial. Am J Transplant 2007; 7: 117-121.
124. Blake P, Sutton D, Cardella CJ., Plasma exchange in acute renal transplant rejection. Prog Clin Biol Res 1990; 337: 249-252.
125. Bonomini V, Vangelista A, Frasca GM, Di Felice A, Liviano D'Arcangelo G., Effects of plasmapheresis in renal transplant rejection: A controlled study. Trans Am Soc Artif Intern Organs 1985; 31: 698-703.
126. Kirubakaran MG, Disney AP, Norman J, Pugsley DJ, Mathew TH., A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation 1981; 32: 164-165.
127. Allen NH, Dyer P, Geoghegan T, Harris K, Lee HA, Slapak M., Plasma exchange in acute renal allograft rejection: A controlled trial. Transplantation 1983; 35: 425-428.
128. Franco A, Anaya F, Niembro E, Ahijado F, Luño J, Valderrábano F., Plasma exchange in the treatment of vascular rejection: Relationship between histological changes and therapeutic response. Transplant Proc 1987; 19: 3661-3663.
129. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-1107.
130. Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63-73.
131. Vangelista A, Frasca GM, Nanni Costa A, Stefoni S, Bonomini V., Value of plasma exchange in renal transplant rejection induced by specific anti-HLA antibodies. Trans Am Soc Artif Intern Organs 1982; 28: 599-603.
132. Macaluso J, Killackey M, Paramesh A, et al. Comparative study of bortezomib therapy for antibody mediated rejection. Am J Transplant 2011; 11 (Suppl 2, Abstract #431): 160.
133. Lubetzky ML, Walker JK, Matignon M, et al. Evolving therapies for antibody mediated rejection: Is bortezomib better than rituximab [abstract SA-PO3065]. World Congress of Nephrology 2011. Vancouver, Canada; 2011.
134. Waiser J, Schutz M, Liefeldt L, Schonemann C, Neumayer H-H, Budde K., Treatment of antibody-mediated renal allograft rejection with bortezomib or rituximab. Am J Transplant 2010; 10 (Suppl 4, Abstract #1504): 466.
135. Sautenet B, Blancho G, Buchler M, et al. One year results of the effects of rituximab on acute humoral rejection in renal transplantation: RITUX ERAH, a multicenter randomized placebo controlled trial. Am J Transplant 2013; 13 (Suppl 5, Abstract #266): 112.
136. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
137. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-S155.
138. Fehr T, Gaspert A., Antibody-mediated kidney allograft rejection: Therapeutic options and their experimental rationale. Transpl Int 2012; 25: 623-632.
139. Smith RN, Malik F, Goes N, et al. Partial therapeutic response to rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl Immunol 2012; 27: 107-113.
140. Clatworthy MR., Targeting B cells and antibody in transplantation. Am J Transplant 2011; 11: 1359-1367.
141. Sato Y, Sahara H, Tsukahara T, et al. Improved generation of HLA class I/peptide tetramers. J Immunol Methods 2002; 271: 177-184.
142. Chen J, Yin H, Xu J, et al. Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig. Am J Transplant 2013; 13: 2280-2292.
143. Heidt S, Hester J, Shankar S, Friend PJ, Wood KJ., B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. Am J Transplant 2012; 12: 1784-1792.
144. Willicombe M, Roufosse C, Brookes P, et al. Antibody-mediated rejection after alemtuzumab induction: Incidence, risk factors, and predictors of poor outcome. Transplantation 2011; 92: 176-182.
145. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: Clinical results and immune monitoring. Am J Transplant 2009; 9: 1087-1098.
146. Martin ST, Tichy EM, Gabardi S., Belatacept: A novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy 2011; 31: 394-407.
147. Lemy A, Toungouz M, Abramowicz D., Bortezomib: A new player in pre- and post-transplant desensitization ? Nephrol Dial Transplant 2010; 25: 3480-3489.
148. Puttarajappa C, Shapiro R, Tan HP., Antibody-mediated rejection in kidney transplantation: A review. J Transplant 2012; 2012: 193724.
149. Webber A., Update on treatment options for antibody-mediated rejection [oral presentation]. Presented at UCSF Transplant Symposium, San Francisco, CA; 2012, September 27-28. Available at: http://www.ucsfcme.com/2012/slides/ MMC13001/12.%20Allison%20Webber.pdf. Accessed July 31, 2013.